170 related articles for article (PubMed ID: 38549044)
1. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.
Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245
[TBL] [Abstract][Full Text] [Related]
7. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
8. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.
Kawachi H; Tamiya M; Taniguchi Y; Yokoyama T; Yokoe S; Oya Y; Imaji M; Okabe F; Kanazu M; Sakata Y; Uematsu S; Tanaka S; Arai D; Saito G; Kobe H; Miyauchi E; Okada A; Hara S; Kumagai T
JTO Clin Res Rep; 2022 Jul; 3(7):100355. PubMed ID: 35769388
[TBL] [Abstract][Full Text] [Related]
10. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
12. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
14. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
17. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
18. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
Li R; Liang H; Li J; Shao Z; Yang D; Bao J; Wang K; Xi W; Gao Z; Guo R; Mu X
BMC Cancer; 2024 Jan; 24(1):107. PubMed ID: 38238648
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study.
Dong X; Huang Y; Yi T; Hu C; Gao Q; Chen Y; Zhang J; Chen J; Liu L; Meng R; Zhang S; Dai X; Fei S; Jin Y; Yin P; Hu Y; Wu G
Front Immunol; 2022; 13():1002938. PubMed ID: 36275698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
